Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNB-101 in advanced solid tumors
NCT04640480Phase 1Completed
- Sponsor
- SN BioScience
- Start
- Oct 2020
- Primary completion
- Jan 2026
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label trial of SNB-101 in colorectal cancer (CRC), breast cancer, pancreatic cancer (PC) and 4 more (7 cohorts), sponsored by SN BioScience. Primary endpoints: Dose-Limiting Toxicity at 18 months, Permanent Discontinuation of SNB-101 and Dose Reduction Due to Adverse Events at 18 months and 4 more. Started Oct 2020; status: completed.
02
Drugs
SNB-101
03
Conditions
colorectal cancer (CRC)breast cancerpancreatic cancer (PC)ovarian cancersmall cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04640480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04640480.